(Q44683749)

5 December 2017

title

Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol (English)

1 reference

5 December 2017

1 reference

1 reference

Thomas P Bersot

1

1 reference

5 December 2017

Guy M Pépin

series ordinal

2

1 reference

5 December 2017

Robert W Mahley

series ordinal

3

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

5 December 2017

published in

American Heart Journal

1 reference

5 December 2017

volume

146

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

1052-1059

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Prediction of Coronary Heart Disease Using Risk Factor Categories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Prevalence of risk factors in men with premature coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Two decades of progress in preventing vascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Plasma lipids and their interrelationship in Turkish adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Prevalence of coronary heart disease in Turkish adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Relatively high coronary death and event rates in Turkish women. Relation to three major risk factors in five-year follow-up of cohort.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Risk factors and cardiovascular disease in Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Body mass index and the prevalence of hypertension and dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Obesity accelerates the progression of coronary atherosclerosis in young men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Obesity, metabolic syndrome, and coronary atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Cholesterol and coronary heart disease: predicting risks by levels and ratios

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Efficacy of lipid profiles in prediction of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipid Research Clinics prevalence cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Serum cholesterol as a prognostic factor after myocardial infarction: the Framingham Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Serum lipids and lipoproteins after myocardial infarction: associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. The CHS Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Relation of serum lipoprotein cholesterol levels to presence and severity of angiographic coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

National Cholesterol Education Program's recommendations, and implications of "missing" high-density lipoprotein cholesterol in cardiac rehabilitation programs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Contributions of the Framingham Study to the conquest of coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900516-7

10.1016/S0002-8703(03)00516-7

7 January 2021

Identifiers

DOI

1 reference

5 December 2017

1 reference